Maternal chronic hepatitis B virus is implicated with low neonatal paraoxonase/arylesterase activities

Clinical Biochemistry

Volumn 41, Issue 4-5, 2008, Pages 282-287

  Schulpis, Kleopatra H ^a   Barzeliotou, Anastasia ^b   Papadakis, Miltiadis ^c   Rodolakis, Alexandros ^c   Antsaklis, Aris ^c   Papassotiriou, Ioannis ^b   Vlachos, George D ^c  

^a Institute of Child Health   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Arylesterase; Delivery; Labour; Neonates; Paraoxonase 1; Pregnancy

Indexed keywords

AMINOTRANSFERASE; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LIVER ENZYME; LOW DENSITY LIPOPROTEIN; VIRUS DNA;

ADULT; ANTIBODY DETECTION; ANTIGEN DETECTION; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DELIVERY ROOM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK POPULATION; HUMAN; LIPID OXIDATION; LIVER FUNCTION TEST; NEWBORN; NONHUMAN; PERINATAL PERIOD; PREGNANT WOMAN; PRIORITY JOURNAL; SPECTROPHOTOMETRY; UMBILICAL CORD BLOOD;

ADULT; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INFANT, NEWBORN; LIVER FUNCTION TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 39049148063     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.10.013     Document Type: Article

References (45)

1. Aldridge W.N. Serum esterases. II. An enzyme hydrolyzing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera. Biochem J 53 (1953) 117-124
2. Mackness M.I., Arrol S., Abbott C., and Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104 (1993) 129-135
3. Nevin D.N., Ambon A., Seidel S.L., and Motulsky A.G. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet 43 (1988) 230-238
4. Furlong C.E., Richter R.J., Min W.K., and Kim J.Q. Genetic variations of the paraoxonase gene in patients with coronary artery disease. Clin Biochem 34 (2001) 475-481
5. Eckerson H.W., Wyte C.M., and La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35 (1983) 1126-1138
6. Playfer J.R., Eze L.C., Bullen M.F., and Evans D.A. Genetic polymorphism and interethnic variability of plasma paroxonase activity. J Med Genet 13 (1976) 337-342
7. Furlong C.E., Li W.F., Richter R.J., et al. Genetic and temporal determinants of pesticide sensitivity: role of paraoxonase (PON1). Neurotoxicology 21 (2000) 91-100
8. Geldmacher V., Mallinckrodt M., and Dieggen T.L. The human paraoxonase-polymorphism and specificity. Toxicol Enu Chem 35 (1988) 214-227
9. Mackness M.I., Harty D., Bhatnagar D., et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 86 (1991) 193-199
10. Karakaya A., Suzen S., Sardas S., Karakaya A.E., and Vural N. Analysis of the serum paraoxonase/arylesterase polymorphism in a Turkish population. Pharmacogenetics 1 (1991) 58-61
11. Eckerson H.W., Romson J., Wyte C., and La Du B.N. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 35 (1983) 214-227
12. Serhatlioglu S., Gursu M.F., Gulcu F., Canatan H., and Godekmerdan A. Levels of paraoxonase and arylesterase activities and malondialdehyde in workers exposed to ionizing radiation. Cell Biochem Funct 21 (2003) 371-375
13. Mackness M.I., Makcness B., Durrington P.N., Connelly P.W., and Hegele R.A. Paraoxonase biochemistry, genetics and relationship to plasma lipoprotein. Curr Opin Lipidol 7 (1996) 69-76
14. Gowri M.S., Van der Westhuyzen D.R., Bridges S.R., and Anderson J.W. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 19 (1999) 2226-2233
15. Sanghera D.K., Sala N., and Kamboh M.I. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 62 (1998) 36-44
16. Burlina A., and Galzigna L. Serum arylesterase isoenzymes in chronic hepatitis. Clin Biochem 7 (1974) 202-205
17. Burlina A., Michielin E., and Galzigna L. Characteristics and behaviour of arylesterase in human serum and liver. Eur J Clin Invest 7 (1977) 17-20
18. Primo-Parmo S.L., Sorenson R.C., Teiber J., and La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33 (1996) 498-507
19. Ferre N., Camps J., Prats E., et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 48 (2002) 262-368
20. Infance-Rivard C., Esnaola S., and Villeneuve J.P. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology 7 (1987) 660-664
21. Wang F.S. Current status and prospects of studies on human genetic alleles associated with hepatitis B virus infection. World J Gactroenterol 9 (2003) 641-644
22. Aviram M., Billecke S., Sorenson R., et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfydryl group and is different from that required for its arylesterase/paraoxonase activities. Arterioscler Thromb Vasc Biol 18 (1998) 1617-1624
23. Aviram M., Rosental M., Billecke S., et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26 (1999) 892-904
24. Berliner J.A., and Heinecke J.W. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 20 (1996) 707-727
25. Burkitt M.J.A. Critical overview of the chemistry of copper-dependent low density lipoprotein oxidation: roles of lipid hydroperoxides, alpha-tocopherol, thiols and ceruloplasmin. Arch Biochem Biophys 394 (2001) 117-135
26. Vlachos G.D., Bartzeliotou A., Schulpis K.H., et al. Maternal-neonatal serum paraoxonase 1 activity in relation to the mode of delivery. Clin Biochem 39 (2006) 923-928
27. Papadakis M., Elefsiniotis I., Vlachos G.D., Daskalakis G., Barbaris C., and Antsaklis A. Intrauterine-transplacental transmission of Hepatitis B virus from hepatitis B, antigen negative (precore mutant G1896A) chronic HBV infected mothers to their infants. Preliminary results of a prospective study. J Clin Virol 38 (2007) 181-183
28. Elefsiniotis S., Glynou I., Magaziotou I., et al. HBeAg negative serological status and low viral replication levels characteristic chronic hepatitis B virus infected women at reproductive age in Greece in one year prospective single-center study. World Gastroenterology 11 B1 (2005) 4879-4882
29. Currum W.F., Jacyna M.R., Hatziyannis S., et al. Mutation preventing information of hepatitis Be antigen in patients with chronic Hepatitis B infection. Lancet 2 (1989) 588-591
30. Miller M.J., Rice Evans C., Davies M.J., Copinathan V., and Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Chim 84 (1993) 407-412
31. Strube M., Haenen G.R., Van der Beta H., and Bast A. Pitfalls in a method for assessment of total antioxidant capacity. Free Radic Res 26 (1997) 515-521
32. Ferre N., Marsillach J., Camps J., et al. Paraoxonase 1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J Hepatol 45 (2006) 51-59
33. Ferre N., Camps J., Fernandez-Ballarat J., et al. Regulation of serum paraoxonases activity by genetic, nutritional and lifestyle factors in the general population. Clin Chem 49 (2003) 1491-1497
34. Boemi M., Levie I., Sirolla C., Pieri C., Marra M., and Janes R.W. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first-degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 155 (2001) 229-235
35. Jaound L., Milochevitch C., and Khalli A. PON1 reduced during HDL oxidation and its capacity. Free Radic Res 37 (2003) 77-83
36. Ferre N., Camps J., Cabre M., Paul A., and Joven J. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism 50 (2001) 997-1000
37. Kono Y., Hayashida K., Tanaka H., Ishibashi H., and Harada M. High-density lipoprotein binding rate differs greatly between genotypes 1b and 2a/2b of hepatitis C virus. J Med Virol 70 (2003) 42-48
38. James R.W., and Deakin S.P. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability and activity. Free Radic Biol Med 37 (2004) 1986-1994
39. Lieber C.S. Role of oxidative stress and antioxidant therapy in alcoholic and non-alcoholic liver diseases. Adv Pharmacol 38 (1997) 601-628
40. Simon H.U., Haj-Yehia A., and Levi Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 5 (2000) 415-418
41. Feldstein A.E., Canbay A., Angulo P., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125 (2003) 437-443
42. Thornberry N.A., and Lazebnik Y. Caspases: enemies within. Science 281 (1998) 1312-1316
43. Sugano M., Tsuchida K., and Makino N. High-density lipoproteins protect endothelial cells from tumor necrosis factor-a-induced apoptosis. Biochem Biophys Res Commun 272 (2000) 872-876
44. Watson A.D., Berliner J.A., Hama S.Y., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96 (1995) 2882-2891
45. Wakatsuki A., Ikenoue N., Okatani Y., Shinohara K., and Fukaya T. Lipoprotein particles in proeclampsia susceptibility to oxidative modification. Obstet Gynecol 96 (2000) 55-59